Mechanism of Wuling powder modulating proBDNF/p75NTR/sortilin and BDNF/TrkB pathways in the treatment of ulcerative colitis complicated with depression

Figure 11  Expression of the brain-derived neurotrophic factor precursor, p75 neurotrophin receptor and sortilin proteins in the hippocampus. A: Expression of brain-derived neurotrophic factor precursor (proBDNF) protein in depression groups; B: Expression of p75 neurotrophin receptor (p75NTR) protein in depression groups; C: Expression of sortilin protein in depression groups; D: Density analysis of proBDNF, p75NTR, and sortilin protein expressions in depression groups; E: Expression of proBDNF protein in chronic restraint stress (CUMS), dextran sodium sulfate (DSS) and compound model groups; F: Expression of p75NTR protein in CUMS, DSS, and compound model groups; G: Expression of sortilin protein in CUMS, DSS, and compound model groups; H: Density analysis of proBDNF, p75NTR, and sortilin protein expressions. ^aP < 0.01 vs control group; ^bP < 0.01 vs chronic restraint stress group; ^cP < 0.01 vs chronic restraint stress + dextran sodium sulfate group; ^dP < 0.01 vs mesalazine group; ^fP < 0.05 vs control group; ^gP < 0.05 vs chronic restraint stress group; ^hP < 0.05 vs chronic restraint stress + dextran sodium sulfate group; ⁱP < 0.05 vs mesalazine group. CUMS: Chronic restraint stress; DSS: Dextran sodium sulfate; LD: Low-dose Wuling powder; MD: Medium-dose Wuling powder; HD: High-dose Wuling powder; FLU: Fluoxetine; MS: Mesalazine; proBDNF: Brain-derived neurotrophic factor precursor; p75NTR: P75 neurotrophin receptor.